Profile data is unavailable for this security.
About the company
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.
- Revenue in USD (TTM)0.00
- Net income in USD-42.49m
- Incorporated2018
- Employees32.00
- LocationCompass Therapeutics Inc.80 Guest StreetBOSTON 02135United StatesUSA
- Phone+1 (617) 500-8099
- Fax+1 (302) 655-5049
- Websitehttps://www.compasstherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P3 Health Partners Inc | 1.27bn | -57.77m | 212.26m | 400.00 | -- | 0.5512 | -- | 0.1676 | -0.6494 | -0.6494 | 13.37 | 1.22 | 1.46 | -- | 13.23 | 3,165,938.00 | -21.46 | -- | -96.06 | -- | 2.50 | 0.1781 | -14.72 | -56.93 | -- | -10.33 | 0.1999 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
Ovid Therapeutics Inc | 391.69k | -52.34m | 212.43m | 40.00 | -- | 2.42 | -- | 542.35 | -0.7415 | -0.7415 | 0.0056 | 1.24 | 0.0026 | -- | -- | 9,792.25 | -34.98 | -20.78 | -37.27 | -23.27 | -- | -- | -13,362.34 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
AVITA Medical Inc | 50.14m | -35.38m | 213.11m | 207.00 | -- | 4.32 | -- | 4.25 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.33 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
Coherus Biosciences Inc | 257.24m | -237.89m | 217.98m | 306.00 | -- | -- | -- | 0.8474 | -2.56 | -2.56 | 2.74 | -1.72 | 0.4633 | 3.14 | 1.39 | 840,666.70 | -42.85 | -21.43 | -74.34 | -29.32 | 38.19 | 79.01 | -92.48 | -36.56 | 1.24 | -4.77 | 1.69 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 219.27m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Werewolf Therapeutics Inc | 16.22m | -41.58m | 219.45m | 46.00 | -- | 1.86 | -- | 13.53 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 219.72m | -- | -- | 11.57 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
Compass Therapeutics Inc. | 0.00 | -42.49m | 220.14m | 32.00 | -- | 1.38 | -- | -- | -0.3343 | -0.3343 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -23.84 | -41.75 | -25.56 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
Agenus Inc | 161.42m | -239.61m | 220.28m | 389.00 | -- | -- | -- | 1.36 | -12.68 | -12.68 | 8.49 | -9.59 | 0.4823 | -- | 170.54 | 414,951.20 | -74.69 | -55.02 | -242.74 | -115.31 | 99.43 | -- | -154.88 | -102.92 | -- | -1.25 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
Lineage Cell Therapeutics Inc | 8.95m | -21.49m | 220.89m | 75.00 | -- | 3.23 | -- | 24.69 | -0.1243 | -0.1243 | 0.0518 | 0.3624 | 0.0796 | -- | 17.17 | 119,266.70 | -19.12 | -19.53 | -22.55 | -22.59 | 92.50 | 89.13 | -240.12 | -370.88 | -- | -- | 0.0023 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
Aldeyra Therapeutics Inc | 0.00 | -30.01m | 223.99m | 10.00 | -- | 1.97 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
2Seventy Bio Inc | 71.20m | -223.22m | 225.15m | 274.00 | -- | 1.09 | -- | 3.16 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
Emergent Biosolutions Inc | 1.19bn | -565.30m | 227.95m | 1.60k | -- | 0.3433 | -- | 0.1923 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
AC Immune SA | 16.33m | -59.84m | 229.15m | 133.00 | -- | 1.29 | -- | 14.03 | -0.7082 | -0.7082 | 0.1923 | 1.79 | 0.0803 | -- | 1.92 | 122,791.30 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
Puma Biotechnology Inc | 226.63m | 15.38m | 232.03m | 185.00 | 14.94 | 4.55 | 8.62 | 1.02 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
Holder | Shares | % Held |
---|---|---|
Adage Capital Management LPas of 31 Dec 2023 | 9.88m | 7.18% |
Janus Henderson Investors US LLCas of 22 Jan 2024 | 7.65m | 5.56% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 5.70m | 4.14% |
Rock Springs Capital Management LPas of 31 Dec 2023 | 5.51m | 4.01% |
Blackstone Alternative Asset Management LPas of 31 Dec 2023 | 4.68m | 3.40% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 4.00m | 2.90% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.99m | 1.45% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.73m | 1.26% |
Avidity Partners Management LPas of 31 Dec 2023 | 1.60m | 1.16% |
Baker Bros. Advisors LPas of 31 Dec 2023 | 1.56m | 1.13% |